Journal
ORAL ONCOLOGY
Volume 51, Issue 5, Pages 423-430Publisher
ELSEVIER
DOI: 10.1016/j.oraloncology.2015.02.092
Keywords
Afatinib; Personalised therapy; EGFR; ErbB; TKI; HPV; EBV; P16; Head and neck squamous cell carcinoma
Categories
Funding
- RNA-Reg CONSOLIDER-Consortium from the Spanish Ministry of Economy and Competitiveness [CSD2009-00080]
- Boehringer Ingelheim
Ask authors/readers for more resources
Head and neck squamous cell carcinoma (HNSCC) represent 95% of head and neck cancer with an incidence of over half a million people globally. The prognosis for patients with recurrent or metastatic HNSCC is generally poor with low 5-year survival rates despite treatment advances over the past few decades. Consequently, it is essential to search for new biomarkers and effective therapy options to optimize HNSCC treatment. Epidermal growth factor receptor (EGFR) is overexpressed in approximately 90% of tumours. EGFR has become one of most common targets for new therapies being investigated in HNSCC. In this way, multiple therapies targeting EGFR in HNSCC have been tested but response rates are still low especially in the recurrent or metastatic setting. This has been attributed to mechanisms of resistance to EGFR-targeted therapies. Afatinib, an oral small molecule ErbB Family Blocker that irreversibly binds to ErbB1 (EGFR), ErbB2 (HER2) and ErbB4 (HER4), is being investigated in HNSCC treatment with encouraging phase II results and several ongoing phase III trials. Results of these trials will help to understand the place of afatinib in the HNSCC treatment armamentarium. (C) 2015 The Authors. Published by Elsevier Ltd.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available